MLTX LAWSUIT ALERT: The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from March 10, 2024, to September 29, 2025, the defendants made materially false and/or misleading statements and failed to disclose critical information regarding their drug candidate SLK and its comparison to BIMZELX [1]. - Specific allegations include: 1. Both SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [1]. 2. SLK's unique Nanobody structure does not provide a clinical benefit over the traditional monoclonal structure of BIMZELX [1]. 3. The supposed increased tissue penetration of SLK does not translate to clinical efficacy [1]. 4. The defendants lacked a reasonable basis for their positive statements about SLK's superiority to monoclonal antibodies [1]. Next Steps for Shareholders - Shareholders who purchased MLTX shares during the class period are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].